Patient preference just reached the 510(k)

Patient preference information has been voluntary since FDA first blessed it in 2016, and the agency’s March 2026 guidance keeps that unchanged. What changed is the door it walks through. For a decade, a sponsor who wanted FDA to weigh a patient’s tolerance for risk alongside the clinical evidence had exactly three routes in: a PMA, a Humanitarian Device Exemption, or a De Novo request. The pathway most device submissions actually use stayed closed.

Three routes, then six

FDA’s original Patient Preference Information guidance, finalized August 24, 2016, named three submission types where patient preference information (PPI) could inform a benefit-risk determination: PMA, HDE, and De Novo. On March 30, 2026, FDA finalized Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle, replacing the 2016 document and widening that list to six — the same three, plus IDE applications, 510(k) premarket notifications, and Breakthrough Device designation requests. The guidance runs the same voluntary-submission logic across every stage FDA now names. It is not a new standard for any of them.

The sentence that didn’t move

Both the 2016 guidance and its 2026 replacement say the same thing about what this does to FDA’s review: nothing. Submitting PPI remains voluntary, and FDA states plainly that doing so does not change the review standard a submission has to meet. Under 21 CFR 860.7(c)(1), FDA still relies only on valid scientific evidence to find reasonable assurance of safety and effectiveness, and 860.7(c)(2) still excludes isolated case reports, random experience, and unsubstantiated opinion from that category, regardless of who collected it or why. A patient preference study that cannot clear 860.7(c)(2) does not become evidence because FDA now accepts it in six submission types instead of three.

Six doors into the same room. The room didn’t get bigger.

Why most 510(k)s still don’t need this door

Naming the 510(k) pathway in a PPI guidance reads, on a skim, like it opens patient preference to the clearance route most device sponsors actually use. It doesn’t, for most of them. A 510(k) turns on substantial equivalence under Section 513(i) of the FD&C Act, and FDA’s own 2018 guidance on benefit-risk factors in 510(k) review is specific about when that becomes a weighing exercise at all: only when the new device has different technological characteristics from its predicate that raise new questions of safety or effectiveness. A 510(k) that clears on equivalent technology never reaches a benefit-risk judgment for PPI to inform in the first place. The 2026 guidance’s 510(k) door opens onto the same narrow hallway that 2018 guidance already built — a different-technological-characteristics submission, weighing whether a device is still as safe and effective as its predicate — not the ordinary 510(k) traffic that never performs that weighing.

What a watching pipeline would never see

Nothing about which submissions used patient preference information lives in a public field. The 510(k) data this product watches — K-number, applicant, product code, decision — carries no indicator for it, and neither does any record FDA posts for a cleared device afterward. A sponsor’s own PPI study, and FDA’s own use of it in a given review, lives in the submission file and, at most, a line in a decision summary FDA chooses to write. Whether collecting patient preference information is worth the cost for a specific device program, across six now-eligible pathways instead of three, is a sponsor’s own regulatory and clinical judgment to make. This is regulatory intelligence and method, never regulatory advice; it describes which pathways changed and which standard didn’t, not which is right for a given device.